Amgen’s oral drug candidate for genital psoriasis delivered positive topline results from a Phase III trial, with both primary and secondary endpoints met by Otezla (apremilast).
Laboratory analysis of the antibody-based Covid-19 therapy GlaxoSmithKline is developing with U.S. partner Vir Biotechnology indicated the drug is effective against the new Omicron variant, the British drugmaker said on December 2.
U.S. President Joe Biden on December 1 unveiled an updated national strategy to combat the AIDS epidemic by boosting money for research, increasing access to treatment, and recognizing the role racism plays in inequitable access to medical services.
Almost one year after Biogen forged a collaboration with Sage Therapeutics worth $1.52 billion, the development deal for the experimental major depressive disorder treatment zuranolone is bearing fruit that will support an expected rolling New Drug Application during 2022.
Moderna Inc. could have a COVID-19 booster shot targeting the Omicron variant tested and ready to file for U.S. authorization as soon as March 2022, the company’s president said on December 1.
BioSpaceVertex Pharmaceuticals reported the company’s Phase II proof-of-concept trial of VX-147 in patients with APOL1-mediated focal segmental glomerulosclerosis (FSGS), with the drug hitting a statistically significant and clinically meaningful decrease of 47.6% in the urine protein to creatinine ratio (UPCR) at Week 13 compared to baseline.
Sanofi is expanding the company’s research into skin therapies after agreeing to acquire the Australian firm Origimm Biotechnology, which specializes in treatments for various types of skin diseases.
BioNTech and Pfizer’s COVID-19 vaccine will likely offer strong protection against any severe disease from the new Omicron virus variant, BioNTech’s Chief Executive told Reuters, as the firm weighs the need to upgrade its commonly used shot.
The U.S. Food and Drug Administration said on November 30 the regulatory agency was evaluating the effectiveness of authorized Covid-19 vaccines against the Omicron coronavirus variant and expects to have more information in the next few weeks.
One day after Bay Area-based Olema Pharmaceuticals announced that falsified information regarding its Phase I/II breast cancer data was circulating across the Internet, the company released topline data for OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN).